Background
==========

*Achromobacter xylosoxidans* is a ubiquitous, environmental gram-negative bacterium, very resistant to antibiotics. Endocarditis caused by these bacteria is extremely rare, with only 20 cases described in the literature to our knowledge. Mortality rates are high \[[@b1-amjcaserep-21-e923031]\], and treatment usually involves a combination of antibiotics and surgery. Nosocomial infections predominate with a strong association between bacteremia and immunosuppression \[[@b2-amjcaserep-21-e923031]\]. Here, we present a case of endocarditis caused by these uncommon bacteria in the native valve in an immunocompetent patient with no recent hospitalizations and a history of cardiac surgery, who survived after a combination of surgical and antibiotic treatment.

Case Report
===========

A 19-year-old man presented with a history of approximately 1 month of intermittent fevers, chills, dry cough, and pleuritic chest pain. He lost about 10 lb during this period and had progressive fatigue. He had a medical history of interatrial and interventricular communication corrected at 11 months of age and aortic coarctation correction at age 10.

On examination, the patient was febrile, tachycardic, and his blood pressure was 125 over 76 mmHg. Physical exam demonstrated diastolic aortic murmur, grade 3/6, compatible with aortic insufficiency. There was no jugular vein distention, the lung exam was clear, and there were no petechiae or signs of skin lesions. The rest of the patient's physical exam was normal. Laboratory testing revealed an elevated white blood cell count of 16.45 10^9^/L and microcytic anemia with hemoglobin of 9.1 g/dL and mean corpuscular volume of 78 fL. Creatinine was 0.71 mg/dL with a glomerular filtration rate above 60 mL/min. An HIV test done on our patient was negative. Chest x-ray showed signs of mild pulmonary congestion and an enlarged cardiac silhouette. An echocardiogram revealed a moderate left atrium enlargement and eccentric left ventricular hyper-trophy with an ejection fraction of 47%. A filamentous structure was also seen inside the patient's left ventricle, adherent to a bicuspid aortic valve, and the ventricular patch in his inter-ventricular septum and severe aortic insufficiency. A diagnosis of endocarditis was given and the patient was placed on gentamicin, oxacillin, and ceftriaxone.

Two sets of blood cultures collected on the patient's admission were positive for presence of *Achromobacter xylosoxidans* sensitive only to carbapenem with minimum inhibitory concentrations (MIC) of 0.5 and resistant to oxacillin and ceftriaxone MIC 16 for both. The antibiotics were switched but the patient continued to have fevers after 7 days of appropriate antibiotics associated with increased shortness of breath and lung congestion compatible with acute heart failure. Subsequent blood cultures performed on Day 5 of antibiotics were still positive. Because of the patient's clinical non-response and acute-onset heart failure associated with aortic insufficiency, a surgical procedure was scheduled \[[@b3-amjcaserep-21-e923031]\].

During the surgery, vegetation was seen on the patient's aortic valve but not on his ventricular patch. Culture of the vegetation showed *A xylosoxidans*. The surgery was done with no major complications. He went to intensive care on moderate doses of vasopressors and was extubated 12 hours after the procedure.

On the fourth day of the patient's hospitalization, he had a spontaneous right-sided pneumothorax, with no apparent cause, which was drained and resolved after 3 days. He went home 10 days after surgery and completed 28 days of carbapenem. His immediate and 30-day echocardiograms at follow-up did not show any vegetation. He was symptomatic at his 6-month and 1-year follow-up appointments.

Discussion
==========

Endocarditis is dangerous and difficult to treat. Prolonged fevers with weight loss in patients with a previous history of heart disease, especially after cardiac surgeries, should raise suspicion of this diagnosis.

*A. xylosoxidans* is an aerobic, motile, gram-negative rod that was first described in 1971 by Yabuuchi and Ohyama, who discovered it in patients with chronic, purulent otitis media \[[@b4-amjcaserep-21-e923031]\]. Infections with *A. xylosoxidans* have included meningitis, pneumonia, peritonitis, and urinary tract infections \[[@b5-amjcaserep-21-e923031],[@b6-amjcaserep-21-e923031]\]. However, bacteremia associated with prosthetic or native valve endocarditis caused by *A. xylosoxidans* is rare.

A recent review published by Barragan, et al. showed that in the majority of cases, patients were immunocompromised and almost all had acquired their infections in the hospital \[[@b7-amjcaserep-21-e923031]\]. Reviewing our patient's records, he had no history of recent or recurrent illnesses or hospitalizations. In most patients, infections associated with this pathogen are related to catheters \[[@b7-amjcaserep-21-e923031],[@b8-amjcaserep-21-e923031]\] but in our report, we do not have a clear source of his infection.

To date, only 20 cases ([Table 1](#t1-amjcaserep-21-e923031){ref-type="table"}) of *A. xylosoxidans* endocarditis have been reported in the literature, of which only two involved a native valve \[[@b8-amjcaserep-21-e923031]--[@b28-amjcaserep-21-e923031]\]. Considering the treatment and outcome: 11 of 19 (58%) required surgical intervention; 8 of 17 (47%) died, 2 of the 8 deaths (22%) were from the operated group and the other 6 (75%) were from the clinically treated group \[[@b10-amjcaserep-21-e923031]\].

Given the scarcity of the cases reported, there is no consensus on the best treatment for *A. xylosoxidans* endocarditis. Antipseudomonal penicillin and carbapenems are the best choices, based on bacteriologic studies and case reports \[[@b11-amjcaserep-21-e923031]\].

In contrast to use of a percutaneous atrial septal occluder device, surgical patch closure of atrial septal defects is known to represent no risk infective endocarditis \[[@b12-amjcaserep-21-e923031]\]. To our knowledge, only two cases of endocarditis on a surgical patch of a ventricular septal defect have been reported \[[@b12-amjcaserep-21-e923031]\]. Considering these previous case reports, it would be unlikely for our patient to have an infection in his patch. However, his bicuspid aortic valve increases his risk of developing endocarditis.

Conclusions
===========

We presented an uncommon and rare case of *A. xylosoxidans* as the cause of infective endocarditis in a young, immunocompetent patient. The bacteria is very resistant and the treatment usually requires broad-spectrum antibiotics associated with surgical procedures. Our patient had a good outcome and was asymptomatic in later follow up.

We thank Dr. Lucia Belem for assistance in gathering data for the report.

###### 

Reported cases of IE.

  **Author**                                            **Age**   **Risk of IE**                        **Comorbidities**                     **Valve**   **Prosthetic**   **Antibiotic**                                                      **Surgery**   **Died**   
  ----------------------------------------------------- --------- ------------------------------------- ------------------------------------- ----------- ---------------- ------------------------------------------------------------------- ------------- ---------- --
  This case                                             19 y      CS, Bicuspid aortic valve             None                                  Ao          No               Meropenem                                                           Yes           No         
  Levoy et al. \[[@b8-amjcaserep-21-e923031]\]          6 m       IVC+ calcified MV                     Arterial calcification                M           No               Piperacillin-tazobactam+ TMP-SMX+colistin+ meropenem+levofloxacin   No            No         
  Tea et al. \[[@b9-amjcaserep-21-e923031]\]            67 y      Rheumatic mitral stenosis, asplenia   Asplenia                              M           No               Piperacillin-sulbactam+ Imipenem                                    Yes           NA         
  Rodrigues et al. \[[@b10-amjcaserep-21-e923031]\]     86 y      None                                  IHD, lung fibrosis, CKD, plymyalgia   Ao          No               Piperacillin-tazobactam+ TMP-SMX                                    No            No         
  Derber et al. \[[@b11-amjcaserep-21-e923031]\]        54 y      PV+ Fallot's T                        Fallot's T                            P           Yes              Piperacillin-tazobactam+ Imipenem-Cilastatin Levofloxacin           Yes           No         
  Kumar et al. \[[@b13-amjcaserep-21-e923031]\]         54 y      NA                                    CKD, CRF, H                           M+Ao        No               Vancomycin+piperacillin-tazobactam+gentamicin                       Yes           NA         
  Rafael et al. \[[@b14-amjcaserep-21-e923031]\]        50 y      CS                                    VSDR                                  P+RVOT      No               NA                                                                  Yes           No         
  Sawant et al. \[[@b15-amjcaserep-21-e923031]\]        62 y      PV+PM                                 AF, CHF, COPD, CKD                    M+Ao+PM     Yes/No/--        Piperacillin-tazobactam+ TMP-SMX+amikacin+ meropenem+rifampicin     Yes           No         
  Tokuyasu et al. \[[@b16-amjcaserep-21-e923031]\]      86 y      PV                                    NA                                    Ao          Yes              Carbapenem                                                          No            Yes        
  Store et al. \[[@b17-amjcaserep-21-e923031]\]         79 y      None                                  H, AF, TIA                            M+Ao        No               Meropenem                                                           No            Yes        
  Malek-Marín et al. \[[@b18-amjcaserep-21-e923031]\]   50 y      Catheter                              CKD                                   NA          --               NA                                                                  Yes           Yes        
  Ahmed et al. \[[@b19-amjcaserep-21-e923031]\]         69 y      PV                                    DM, H, CKD, CABG                      M+Ao        No/Yes           Ertapenem+Tigecycline+ TMP-SMX                                      Yes           Yes        
  van Hal et al. \[[@b20-amjcaserep-21-e923031]\]       37 y      PV+IDU                                NA                                    Ao          Yes              Carbapenem                                                          Yes           No         
  Yang et al. \[[@b21-amjcaserep-21-e923031]\]          35 y      IDU+TR+MP                             Hepatitis C                           T           No               Piperacillin-tazobactam+ Amikacin+Ceftazidime                       Yes           NA         
  Nanuashvili et al. \[[@b22-amjcaserep-21-e923031]\]   46 y      None                                  DM, Emphysema, IS                     M+Ao        No               Ampicillin+Sulbactam+ Cotrimoxazole                                 Yes           No         
  Ahn et al. \[[@b23-amjcaserep-21-e923031]\]           35 y      CS+PM                                 VSDR, CHB with PM                     PM+RVOT     --               Ceftazidime+Amikacin                                                Yes           No         
  Martino et al. \[[@b24-amjcaserep-21-e923031]\]       33 y      IVC                                   Bone marrow transplant                NA          --               Aztreonam+Amikacin                                                  No            Yes        
  Davis et al. \[[@b25-amjcaserep-21-e923031]\]         30 y      NA                                    HF                                    NA          --               None                                                                No            Yes        
  Lofgren et al. \[[@b26-amjcaserep-21-e923031]\]       77 y      PV                                    Rheumatic dis.+ PV                    M+Ao        No/Yes           Tobramycin+Carbenicillin+ TMP-SMX+Moxalactam                        No            Yes        
  Bhattarai et al. \[[@b27-amjcaserep-21-e923031]\]     37 y      IDU+PV                                NA                                    M           Yes              Meropenem                                                           Yes           No         
  Olson et al. \[[@b28-amjcaserep-21-e923031]\]         35 y      Aortic surgery+PV                     NA                                    Ao          Yes              Carbenicillin+ TMP-SMX+ Rifampicin+ Moxalactam+Azlocillin           No            Yes        

AF -- atrial fibrillation; Ao -- aortic; CABG -- coronary artery bypass grafting; CHB -- complete heart block; CHF -- congestive heart failure; CKD -- chronic kidney disease; COPD -- chronic obstructive pulmonary disease; CS -- cardiac surgery; DM -- diabetes mellitus; H -- hypertension; HF -- heart failure; IDU -- intravenous drug user; IHD -- ischemic heart disease; IS -- ischemic stroke; IVC -- intravenous catheter; M -- mitral; NA -- not available; P -- pulmonary; PM -- pacemaker; PV -- prosthetic valve; RVOT -- right ventricular outflow tract; T -- tricuspid; TIA -- transient ischemic accident; TMP-SMX -- trimethoprim-sulfamethoxazole; TR -- tricuspid regurgitation; VSDR -- ventricular septal defect repair.
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